Survival curves of patients with NPM1-mutated AML (MLD⁺ vs MLD⁻) from GIMEMA LAM99P and GIMEMA/EORTC AML12 trials. (A) No significant differences in OS are observed between NPM1-mutated AML with (red line) and without (blue line) MLD (P = .608). (B) No significant differences in EFS are observed between NPM1-mutated AML with (red line) and without (blue line) MLD (P = .367). (C) No significant differences in OS are observed between normal karyotype NPM1-mutated AML with (red line) and without (blue line) MLD (P = .862). (D) No significant differences in EFS are observed between normal karyotype NPM1-mutated AML with and without MLD (P = .541).